Seribantumab has been used in trials studying the treatment of NSCLC, Heregulin, Adenocarcinoma, Colorectal Cancer, and Solid Tumor Cancers, among others.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Seribantumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Seribantumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Seribantumab. |
| Estrone | Estrone may increase the thrombogenic activities of Seribantumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Seribantumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Seribantumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Seribantumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Seribantumab. |
| Estriol | Estriol may increase the thrombogenic activities of Seribantumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Seribantumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Seribantumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Seribantumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Seribantumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Seribantumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Seribantumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Seribantumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Seribantumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Seribantumab. |
| Equol | Equol may increase the thrombogenic activities of Seribantumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Seribantumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Seribantumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Seribantumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Seribantumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Seribantumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Seribantumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Seribantumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Seribantumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Seribantumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Seribantumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Seribantumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Seribantumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Seribantumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Seribantumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Seribantumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Seribantumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Seribantumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Seribantumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Seribantumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Seribantumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Seribantumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Seribantumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Seribantumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Seribantumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Seribantumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Seribantumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Seribantumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Seribantumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Seribantumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Seribantumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Seribantumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Seribantumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Seribantumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Seribantumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Seribantumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Seribantumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Seribantumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Seribantumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Seribantumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Seribantumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Seribantumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Seribantumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Seribantumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Seribantumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Seribantumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Seribantumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Seribantumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Seribantumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Seribantumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Seribantumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Seribantumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Seribantumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Seribantumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Seribantumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Seribantumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Seribantumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Seribantumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Seribantumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Seribantumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Seribantumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Seribantumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Seribantumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Seribantumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Seribantumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Seribantumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Seribantumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Seribantumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Seribantumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Seribantumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Seribantumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Seribantumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Seribantumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Seribantumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Seribantumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Seribantumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Seribantumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Seribantumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Seribantumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Seribantumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Seribantumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Seribantumab. |